版本:
中国

BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin

May 8 Oncolytics Biotech Inc:

* Oncolytics Biotech Inc announces FDA fast track designation for Reolysin in metastatic breast cancer

* Oncolytics Biotech-based on co's understanding of Reolysin, is pursuing metastatic breast cancer as its primary focus for late-stage clinical testing Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐